<p>Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - 獲取免費報告) 的股價在週一交易中達到了新的 52 周高點，此前花旗集團將該股票的目標價從 45.00 美元上調至 50.00 美元。花旗集團目前對該股票給予買入評級。Kiniksa Pharmaceuticals International 的股價最高達到 39.57 美元，最後交易於 39.37 美元，成交量為 280711 股。該股票此前收於 38.64 美元。</p>
<p>其他幾家券商也對 KNSA 發佈了報告。Zacks Research 在 10 月 6 日的研究報告中將 Kiniksa Pharmaceuticals International 的評級從 “強力買入” 下調至 “持有”。Wall Street Zen 在 10 月 3 日的報告中將 Kiniksa Pharmaceuticals International 的評級從 “強力買入” 下調至 “買入”。Jefferies Financial Group 在 7 月 29 日的報告中將 Kiniksa Pharmaceuticals International 的目標價從 45.00 美元上調至 54.00 美元，並給予該公司 “買入” 評級。Wedbush 在 10 月 13 日的報告中將 Kiniksa Pharmaceuticals International 的目標價從 38.00 美元上調至 44.00 美元，並給予該公司 “跑贏大盤” 評級。最後，TD Cowen 在 9 月 29 日的研究報告中開始覆蓋 Kiniksa Pharmaceuticals International 的股票。他們對該股票給予 “買入” 評級，目標價為 60.00 美元。七位股票研究分析師對該股票給予買入評級，兩位給予持有評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 46.86 美元。</p>
<p><strong>查看我們關於 KNSA 的最新研究報告</strong></p>
<h2>內部買賣</h2>
<p>在相關消息中，董事 Thomas Malley 在 8 月 14 日的交易中出售了 78,233 股 Kiniksa Pharmaceuticals International 的股票。該股票以平均價格 33.09 美元出售，總交易額為 2,588,729.97 美元。出售後，該董事直接持有公司 12,546 股股票，價值約 415,147.14 美元。這筆交易代表了他們持股的 86.18% 的減少。該出售在與 SEC 的法律文件中披露，您可以通過此鏈接訪問。此外，內部人士 John F. Paolini 在 8 月 6 日的交易中出售了 29,325 股公司的股票。這些股票以平均價格 32.55 美元出售，總價值為 954,528.75 美元。交易完成後，內部人士持有 57,403 股公司的股票，價值為 1,868,467.65 美元。這筆交易代表了他們持股的 33.81% 的減少。該出售的披露可以在這裏找到。內部人士在上個季度共出售了 596,839 股公司股票，價值為 20,357,964 美元。公司內部人士持有 53.48% 的公司股票。</p>
<h2>機構資金流入和流出</h2>
<p>一些對沖基金和其他機構投資者最近增加或減少了對 KNSA 的持股。GAMMA Investing LLC 在第一季度將其在 Kiniksa Pharmaceuticals International 的股份增加了 84.8%。GAMMA Investing LLC 現在擁有 1,238 股公司股票，價值 27,000 美元，此前在上個季度購買了 568 股。Wealth Enhancement Advisory Services LLC 在第一季度購買了 Kiniksa Pharmaceuticals International 的新頭寸，價值 301,000 美元。Asset Management One Co. Ltd.在第一季度購買了 Kiniksa Pharmaceuticals International 的新頭寸，價值 41,000 美元。Wealthquest Corp 在第一季度購買了 Kiniksa Pharmaceuticals International 的新股份，價值約 42,000 美元。最後，AMI Asset Management Corp 在第一季度將其在 Kiniksa Pharmaceuticals International 的股份增加了 50.3%。AMI Asset Management Corp 現在擁有 77,688 股公司股票，價值 1,725,000 美元，此前在此期間又收購了 26,010 股。53.95% 的股票目前由對沖基金和其他機構投資者持有。</p>
<h2>Kiniksa Pharmaceuticals International 的價格表現</h2>
<p>該公司的市值為 29 億美元，市盈率為 981.10，貝塔值為 0.16。公司的 50 日簡單移動平均為 35.85 美元，200 日簡單移動平均為 29.82 美元。</p>
<p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - 獲取免費報告) 最近在 7 月 29 日發佈了季度財報。公司報告每股收益（EPS）為 0.23 美元，超出市場共識預期的 0.18 美元，超出幅度為 0.05 美元。Kiniksa Pharmaceuticals International 的淨利潤率為 0.90%，股本回報率為 1.05%。公司季度收入為 1.568 億美元，而分析師預期為 1.4521 億美元。Kiniksa Pharmaceuticals International 已將其 2025 財年的指引設定為每股收益。分析師預計 Kiniksa Pharmaceuticals International, plc 在當前財年將發佈-0.55 美元的每股收益。</p>
<h2>關於 Kiniksa Pharmaceuticals International</h2>
<p>(獲取免費報告)</p>
<p>Kiniksa Pharmaceuticals, Ltd.是一家生物製藥公司，專注於發現、收購、開發和商業化治療藥物，以滿足全球患有重大未滿足醫療需求的虛弱疾病患者的需求。其產品候選包括 ARCALYST，一種針對複發性心包炎的白細胞介素-1α和白細胞介素-1β的治療藥物，這是一種炎症性心血管疾病；Mavrilimumab，一種單克隆抗體抑制劑，已完成針對鉅細胞動脈炎的二期臨牀試驗；Vixarelimab，一種單克隆抗體，正在進行針對結節性瘙癢症的 2b 期臨牀試驗，這是一種慢性炎症性皮膚病；以及 KPL-404，一種 CD40-CD154 相互作用的單克隆抗體抑制劑，這是 B 細胞成熟、免疫球蛋白類別轉換和 1 型免疫反應的關鍵 T 細胞共刺激信號。</p>
<h2>特色故事</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Kiniksa Pharmaceuticals International</li>
<li>最佳航空航天股票投資</li>
<li>5 只令人驚訝的股票，將從未來的機器人熱潮中受益</li>
<li>如何投資 FAANG 股票</li>
<li>3 只被低估的大型股，看起來適合反彈</li>
<li>股票中的死亡交叉是什麼？</li>
<li>Meta 與 OpenAI：Sora 是否對 Meta 的主導地位構成真正威脅？</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Kiniksa Pharmaceuticals International 嗎？</h2>
<p>在考慮 Kiniksa Pharmaceuticals International 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Kiniksa Pharmaceuticals International 並不在名單上。</p>
<p>雖然 Kiniksa Pharmaceuticals International 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

KNSA

<p>Kiniksa Pharmaceuticals International（納斯達克代碼：KNSA）在花旗集團將其目標價從 45 美元上調至 50 美元並維持買入評級後，達到了 39.57 美元的新 52 周高點。其他分析師的評級則各有不同，Zacks 將評級下調至持有，而 Jefferies 則將目標價上調至 54 美元。內部人士最近出售了大量股份，機構投資者持有 53.95% 的股份。Kiniksa 報告的季度每股收益為 0.23 美元，超出預期，市值為 29 億美元，市盈率為 981.10</p>

<p>Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report)'s share price reached a new 52-week high during trading on Monday after Citigroup raised their price target on the stock from $45.00 to $50.00. Citigroup currently has a buy rating on the stock. Kiniksa Pharmaceuticals International traded as high as $39.57 and last traded at $39.37, with a volume of 280711 shares. The stock had previously closed at $38.64.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - 獲取免費報告) 的股價在週一交易中達到了新的 52 周高點，此前花旗集團將該股票的目標價從 45.00 美元上調至 50.00 美元。花旗集團目前對該股票給予買入評級。Kiniksa Pharmaceuticals International 的股價最高達到 39.57 美元，最後交易於 39.37 美元，成交量為 280711 股。該股票此前收於 38.64 美元。</p>
</div><p>Several other brokerages have also issued reports on KNSA. Zacks Research lowered Kiniksa Pharmaceuticals International from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, October 6th. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Friday, October 3rd. Jefferies Financial Group boosted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, July 29th. Wedbush boosted their price objective on Kiniksa Pharmaceuticals International from $38.00 to $44.00 and gave the company an &#34;outperform&#34; rating in a report on Monday, October 13th. Finally, TD Cowen began coverage on shares of Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They issued a &#34;buy&#34; rating and a $60.00 price target on the stock. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $46.86.</p>
<div class="lb-trans"><p>其他幾家券商也對 KNSA 發佈了報告。Zacks Research 在 10 月 6 日的研究報告中將 Kiniksa Pharmaceuticals International 的評級從 “強力買入” 下調至 “持有”。Wall Street Zen 在 10 月 3 日的報告中將 Kiniksa Pharmaceuticals International 的評級從 “強力買入” 下調至 “買入”。Jefferies Financial Group 在 7 月 29 日的報告中將 Kiniksa Pharmaceuticals International 的目標價從 45.00 美元上調至 54.00 美元，並給予該公司 “買入” 評級。Wedbush 在 10 月 13 日的報告中將 Kiniksa Pharmaceuticals International 的目標價從 38.00 美元上調至 44.00 美元，並給予該公司 “跑贏大盤” 評級。最後，TD Cowen 在 9 月 29 日的研究報告中開始覆蓋 Kiniksa Pharmaceuticals International 的股票。他們對該股票給予 “買入” 評級，目標價為 60.00 美元。七位股票研究分析師對該股票給予買入評級，兩位給予持有評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 46.86 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on KNSA</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 KNSA 的最新研究報告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In related news, Director Thomas Malley sold 78,233 shares of Kiniksa Pharmaceuticals International stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $33.09, for a total transaction of $2,588,729.97. Following the sale, the director directly owned 12,546 shares in the company, valued at approximately $415,147.14. This trade represents a 86.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John F. Paolini sold 29,325 shares of the company's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $32.55, for a total value of $954,528.75. Following the completion of the transaction, the insider owned 57,403 shares of the company's stock, valued at $1,868,467.65. This trade represents a 33.81% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 596,839 shares of company stock valued at $20,357,964 over the last quarter. Corporate insiders own 53.48% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，董事 Thomas Malley 在 8 月 14 日的交易中出售了 78,233 股 Kiniksa Pharmaceuticals International 的股票。該股票以平均價格 33.09 美元出售，總交易額為 2,588,729.97 美元。出售後，該董事直接持有公司 12,546 股股票，價值約 415,147.14 美元。這筆交易代表了他們持股的 86.18% 的減少。該出售在與 SEC 的法律文件中披露，您可以通過此鏈接訪問。此外，內部人士 John F. Paolini 在 8 月 6 日的交易中出售了 29,325 股公司的股票。這些股票以平均價格 32.55 美元出售，總價值為 954,528.75 美元。交易完成後，內部人士持有 57,403 股公司的股票，價值為 1,868,467.65 美元。這筆交易代表了他們持股的 33.81% 的減少。該出售的披露可以在這裏找到。內部人士在上個季度共出售了 596,839 股公司股票，價值為 20,357,964 美元。公司內部人士持有 53.48% 的公司股票。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KNSA. GAMMA Investing LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after purchasing an additional 568 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $301,000. Asset Management One Co. Ltd. bought a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $41,000. Wealthquest Corp purchased a new stake in Kiniksa Pharmaceuticals International in the 1st quarter worth about $42,000. Finally, AMI Asset Management Corp raised its stake in Kiniksa Pharmaceuticals International by 50.3% in the 1st quarter. AMI Asset Management Corp now owns 77,688 shares of the company's stock valued at $1,725,000 after acquiring an additional 26,010 shares during the period. 53.95% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近增加或減少了對 KNSA 的持股。GAMMA Investing LLC 在第一季度將其在 Kiniksa Pharmaceuticals International 的股份增加了 84.8%。GAMMA Investing LLC 現在擁有 1,238 股公司股票，價值 27,000 美元，此前在上個季度購買了 568 股。Wealth Enhancement Advisory Services LLC 在第一季度購買了 Kiniksa Pharmaceuticals International 的新頭寸，價值 301,000 美元。Asset Management One Co. Ltd.在第一季度購買了 Kiniksa Pharmaceuticals International 的新頭寸，價值 41,000 美元。Wealthquest Corp 在第一季度購買了 Kiniksa Pharmaceuticals International 的新股份，價值約 42,000 美元。最後，AMI Asset Management Corp 在第一季度將其在 Kiniksa Pharmaceuticals International 的股份增加了 50.3%。AMI Asset Management Corp 現在擁有 77,688 股公司股票，價值 1,725,000 美元，此前在此期間又收購了 26,010 股。53.95% 的股票目前由對沖基金和其他機構投資者持有。</p>
</div><h2>Kiniksa Pharmaceuticals International Price Performance</h2>
<div class="lb-trans"><h2>Kiniksa Pharmaceuticals International 的價格表現</h2>
</div><p>The firm has a market capitalization of $2.90 billion, a PE ratio of 981.10 and a beta of 0.16. The company's fifty day simple moving average is $35.85 and its 200 day simple moving average is $29.82.</p>
<div class="lb-trans"><p>該公司的市值為 29 億美元，市盈率為 981.10，貝塔值為 0.16。公司的 50 日簡單移動平均為 35.85 美元，200 日簡單移動平均為 29.82 美元。</p>
</div><p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The company had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals International (NASDAQ:KNSA - 獲取免費報告) 最近在 7 月 29 日發佈了季度財報。公司報告每股收益（EPS）為 0.23 美元，超出市場共識預期的 0.18 美元，超出幅度為 0.05 美元。Kiniksa Pharmaceuticals International 的淨利潤率為 0.90%，股本回報率為 1.05%。公司季度收入為 1.568 億美元，而分析師預期為 1.4521 億美元。Kiniksa Pharmaceuticals International 已將其 2025 財年的指引設定為每股收益。分析師預計 Kiniksa Pharmaceuticals International, plc 在當前財年將發佈-0.55 美元的每股收益。</p>
</div><h2>About Kiniksa Pharmaceuticals International</h2>
<div class="lb-trans"><h2>關於 Kiniksa Pharmaceuticals International</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.</p>
<div class="lb-trans"><p>Kiniksa Pharmaceuticals, Ltd.是一家生物製藥公司，專注於發現、收購、開發和商業化治療藥物，以滿足全球患有重大未滿足醫療需求的虛弱疾病患者的需求。其產品候選包括 ARCALYST，一種針對複發性心包炎的白細胞介素-1α和白細胞介素-1β的治療藥物，這是一種炎症性心血管疾病；Mavrilimumab，一種單克隆抗體抑制劑，已完成針對鉅細胞動脈炎的二期臨牀試驗；Vixarelimab，一種單克隆抗體，正在進行針對結節性瘙癢症的 2b 期臨牀試驗，這是一種慢性炎症性皮膚病；以及 KPL-404，一種 CD40-CD154 相互作用的單克隆抗體抑制劑，這是 B 細胞成熟、免疫球蛋白類別轉換和 1 型免疫反應的關鍵 T 細胞共刺激信號。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than Kiniksa Pharmaceuticals International</li>
<li>Best Aerospace Stocks Investing</li>
<li>5 Surprising Stocks Set to Benefit From a Future Robotics Boom</li>
<li>How to Invest in the FAANG Stocks</li>
<li>3 Oversold Large-Caps That Look Ripe for a Rebound</li>
<li>What is a Death Cross in Stocks?</li>
<li>Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Kiniksa Pharmaceuticals International</li>
<li>最佳航空航天股票投資</li>
<li>5 只令人驚訝的股票，將從未來的機器人熱潮中受益</li>
<li>如何投資 FAANG 股票</li>
<li>3 只被低估的大型股，看起來適合反彈</li>
<li>股票中的死亡交叉是什麼？</li>
<li>Meta 與 OpenAI：Sora 是否對 Meta 的主導地位構成真正威脅？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Kiniksa Pharmaceuticals International Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Kiniksa Pharmaceuticals International 嗎？</h2>
</div><p>Before you consider Kiniksa Pharmaceuticals International, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Kiniksa Pharmaceuticals International 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals International wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Kiniksa Pharmaceuticals International 並不在名單上。</p>
</div><p>While Kiniksa Pharmaceuticals International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Kiniksa Pharmaceuticals International 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Kiniksa Pharmaceuticals International（納斯達克股票代碼：KNSA）在分析師上調評級後創下 52 周新高